BACKGROUND: Due to limited resources within the health service and the continuous discussion on cost containment, economic criteria should also be considered when assessing therapy concepts. Particular results in terms of economic efficiency reserves are to be expected from a transfer of care from the in- @entity1 to the out- @entity1 sector. METHODS: In a prospective, direct cost recording of all relevant uses of resources, the direct and indirect costs of the treatment of 14 @entity1 with @entity1577 ( @entity1577 ) were included in the cross-over-design. The quality of life was recorded at least once for each @entity1 using the EuroQol. In-patient intravenous antibiotic therapy carried out during the block of out- @entity1 care served as one of the disqualification criteria when selecting @entity1 . RESULT: Over an observation period of nine months, the average direct cost recorded were @entity3918 35,706 for out- @entity1 and @entity3918 40,143 for in- @entity1 treatment (+15%). As far as indirect costs are concerned, the losses of production in the national economy recorded for in- @entity1 treatment were 80% higher. CONCLUSION: The direct and indirect costs for in- @entity1 @entity1577 -therapy are in total higher than for out- @entity1 care. Whether these cost advantages have to be "bought" with lower medical effectiveness needs to be demonstrated by further clinical studies. In the sense of the disease management approach, the results of this study should be used to help rationally weigh up the costs of out- @entity1 care against alternative treatment concepts.

[Economic aspects in treatment of XXXX with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3918 :: ('MESH:D009223', 'Disease') :: ['DM'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['CF', 'cystic fibrosis']
@entity1577 :: (MESH:D003550,Disease) :: ['cystic fibrosis']
